1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/18275
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKalambokis, G.en
dc.contributor.authorKorantzopoulos, P.en
dc.contributor.authorNikas, S. A.en
dc.contributor.authorTheodorou, A.en
dc.contributor.authorTsianos, E. V.en
dc.date.accessioned2015-11-24T18:51:33Z-
dc.date.available2015-11-24T18:51:33Z-
dc.identifier.issn0168-8278-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18275-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAntihypertensive Agents/administration & dosage/*therapeutic useen
dc.subjectFollow-Up Studiesen
dc.subjectHumansen
dc.subjectHypertension, Portal/complications/*drug therapyen
dc.subjectHypertension, Pulmonary/complications/*drug therapyen
dc.subjectInjections, Intravenousen
dc.subjectLypressin/administration & dosage/*analogs & derivatives/therapeutic useen
dc.subjectMaleen
dc.subjectShock, Septicen
dc.subjectTime Factorsen
dc.titleSignificant improvement of portopulmonary hypertension after 1-week terlipressin treatmenten
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1016/j.jhep.2007.12.012-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/18280605-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0168827808000457/1-s2.0-S0168827808000457-main.pdf?_tid=31a3fed2d7b14a78b38318023b5a1302&acdnat=1334041539_5b8706491eb3f1263ba4e87ca07015dd-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2008-
heal.abstractCirrhosis associated with moderate and severe portopulmonary hypertension carries a poor prognosis. Optimal management has not yet been defined. Current treatment options, such as prostacyclin analogues, endothelin antagonists, and phosphodiesterase-5 inhibitors, are characterized by slow onset of action and various adverse effects, particularly in patients with advanced cirrhosis. Here, we report the significant reduction of pulmonary arterial pressure after 1-week terlipressin treatment in a patient with concomitant hepato-renal syndrome. Terlipressin could be a novel and safe treatment for portopulmonary hypertension.en
heal.journalNameJ Hepatolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Kalambokis-2008-Significant improvem.pdf83.11 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons